Overview

Ivosidenib is a small-molecule inhibitor of mutant isocitrate dehydrogenase 1. Its clinical value comes from a precise mechanism: it targets a single mutated enzyme that drives a distinct subset of leukemias and cholangiocarcinomas. The 250 mg tablet offered here is formulated for oral administration in those IDH1-mutated settings.

The IDH1 Mutation and Its Oncometabolite

In normal cells, IDH1 helps convert isocitrate to alpha-ketoglutarate. A neomorphic mutation, most often at the R132 codon, redirects the enzyme to produce 2-hydroxyglutarate, an oncometabolite. Elevated 2-HG interferes with cellular differentiation and supports tumor development in both blood and biliary tract cancers.

How Ivosidenib Acts

Ivosidenib binds the mutant IDH1 enzyme and suppresses production of 2-hydroxyglutarate. Clinical pharmacology studies show marked reductions in circulating and tissue 2-HG levels after dosing. As the oncometabolite falls, blocked differentiation pathways can resume, which underlies the therapeutic effect rather than a direct cytotoxic attack.

Where the Mechanism Translates to Indications

Because the driver is the mutation itself, eligibility depends on testing. Ivosidenib is used in adult patients with relapsed or refractory acute myeloid leukemia carrying an IDH1 mutation, in newly diagnosed AML for patients who are older or unfit for intensive chemotherapy, and in previously treated IDH1-mutated cholangiocarcinoma. Detection of the mutation is the gate to therapy.

Differentiating From Other AML Approaches

Unlike cytotoxic chemotherapy, ivosidenib is directed at a specific mutated enzyme rather than dividing cells broadly, which frames it as a targeted option. It is also distinct from IDH2 inhibitors, which address a different isoform, and from FLT3-targeted agents used in other AML subsets. Because eligibility rests on mutation testing, the diagnostic step is inseparable from therapy. This logic also explains why the same molecule is relevant in cholangiocarcinoma, a separate disease unified by the shared IDH1 alteration. Monitoring during therapy focuses on differentiation syndrome, a known risk requiring prompt recognition and corticosteroids, with regular assessment of blood counts and chemistry.

FAQ

Q: Does ivosidenib work without an IDH1 mutation? A: No. The drug is directed at the mutant enzyme, so an IDH1 mutation must be confirmed before treatment is considered.

Q: What is the main thing 2-hydroxyglutarate does in these cancers? A: It accumulates because of the mutation and disrupts normal cell differentiation, which the inhibitor helps reverse by lowering its level.

Q: Is the 250 mg strength the standard dose form? A: The oral formulation is provided as 250 mg tablets, and the product offered here is presented in that strength for the indicated settings.